Fig. 4: MPT0B291 inhibits the growth of GBM and TMZ-resistant GBM.

A Primary mouse glial cells were treated with DMSO or indicated concentrations of MPT0B291, tubacin, nexturastat A, and tubastatin A for 2 days. After treatment, the proportion of surviving cells was estimated using the MTT assay. Quantitative result (relative to DMSO) from three independent experiments is shown. B P1s cells (a), U87MG (b), U87MG-R (c), A172 (d), A172-R (e), P3 (f), and P3-R (g) were treated with the indicated concentrations of MPT0B291 for 4 days. After treatment, the proportion of surviving cells was estimated using the MTT assay. Data (relative to Day 0) are representative of three independent experiments and presented as the mean ± SEM. C Tumors with DMSO or 10 mg/kg MPT0B291 treatment from SCID mice implanted with U87MG cells for 6 weeks are shown (a), and quantitative result of tumor weights is shown (b). D U87MG (a) or P1s cells (b) inoculated orthotopic mice were randomly grouped and treated with DMSO, 10 mg/kg TMZ (for P1s cells inoculated orthotopic mice) or 10 mg/kg MPT0B291 three days/week thereafter from day 5. Results of the Kaplan–Meier curve for the duration of survival in the control group (blue line) and MPT0B291-treated group (red line) are shown. E γH2AX levels in xenograft tumors were studied using IHC staining (a), and quantified (b) using ImageJ analysis with the IHC profiler score (n = 10). H&E staining of xenograft tumors (c) for nuclei counting using ImageJ analysis (d).